Colchicine significantly reduces the risk of first and total ischemic cardiovascular events by 23% and 34% respectively in addition to standard of care in patients with a recent myocardial...

MONTREAL, Nov. 16, 2019 (GLOBE NEWSWIRE) -- The Montreal Heart Institute (MHI) today announced results from the COLchicine Cardiovascular Outcomes Trial (COLCOT) which compared colchicine to placebo on top of standard of care in preventing ischemic cardiovascular events in patients with a recent myocardial infarction (MI). In this study, patients receiving colchicine 0.5mg daily had a significantly lower rate of first and total (first and recurrent) ischemic cardiovascular events than those on placebo1. These data are simultaneously published in the New England Journal of Medicine (NEJM) and presented today at the American Heart Association (AHA) late-breaking Scientific Session.
The primary efficacy endpoint was a composite of cardiovascular death, resuscitated cardiac arrest, MI, stroke or urgent hospitalization for angina requiring coronary revascularization1. Patients were also treated according to national guidelines that included the intensive use of statins1.Treatment with colchicine resulted in a:

23% reduction in the risk of a first event of the primary efficacy endpoint; with event rates of 5.5% with colchicine and 7.1% with placebo (HR, 0.77; 95% CI, 0.61-0.96; p=0.02) 1.A 

34% reduction in the risk of total (first and recurrent) events of the primary efficacy endpoint (RR, 0.66, 95% CI, 0.51-0.86, p=0.002) 1.

29% reduction in the risk of a first event of the primary efficacy endpoint in patients who adhered to the protocol; with event rates of 5.1% with colchicine and 7.1% with placebo (HR, 0.71; 95% CI, 0.56-0.90) 1.

a??COLCOT exemplifies how to bring innovation in a time- and cost-effective manner to patients by repurposing older drugs,a?? said Dr. Jean-Claude Tardif, Director of the Research Center at the Montreal Heart Institute, Professor of Medicine at the University of Montreal, and COLCOT primary investigator. a??These data underscore the potential of colchicine as an efficient and critically needed therapy for reducing inflammation post-myocardial infarction to improve patient cardiovascular outcomes.a??In COLCOT, 4,745 patients were randomized within 30 days of an MI to receive colchicine 0.5mg daily or placebo, on top of their standard of care, and were followed for a median of 23 months1. Colchicine was generally well-tolerated with nausea in 1.8% and 1.0% (p=0.02) of patients in the colchicine and placebo groups respectively1. Pneumonia was reported as a serious adverse event in 0.9% of colchicine patients compared with 0.4% in the placebo group (p=0.03).
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Август 2022    »